|
Nutanix, Inc. ("we," "us," "our" or "Nutanix") provides a leading enterprise cloud platform, which we call the Nutanix Cloud Platform, that consists of software solutions and cloud services that power our customers’ enterprise infrastructure. Our solutions run across private-, hybrid- and multicloud environments, and allow organizations to seamlessly "lift and shift" their workloads, including enterprise applications, high-performance databases, end-user computing and virtual desktop infrastructure ("VDI") services, cloud native workloads, and analytics applications, between different cloud environments. Our goal is to provide a single, simple, open software platform for all hybrid and multicloud applications and data.
9-21-2021 |
Dr. Rajiv Ramaswami
Chief Executive Officer Nutanix, Inc. 1740 Technology Drive Suite 150 San Jose, CA 95110 United States 408-216-8360 http://www.nutanix.com Nasdaq Stock Symbol NTNX |
|
We are a global medical technology company focused on developing, manufacturing, selling and providing procedural solutions for spine surgery, with a guiding purpose to transform surgery, advance care and change lives. We offer a comprehensive portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. In addition, we develop and sell magnetically adjustable implant systems for spine and specialized orthopedic procedures. For the year ended December 31, 2021, we generated net sales of $1.1 billion, including sales in more than 50 countries.
2-23-2022 |
Mr. J. Christopher Barry
President NuVasive, Inc 7475 Lusk Boulevard San Diego, CA 92121 United States 858-909-1800 http://www.nuvasive.com Nasdaq Stock Symbol NUVA |
|
NVIDIA pioneered accelerated computing to help solve the most challenging computational problems. Since our original focus on PC graphics, we have expanded to several other large and important computationally intensive fields. Fueled by the sustained demand for exceptional 3D graphics and the scale of the gaming market, NVIDIA has leveraged its GPU architecture to create platforms for scientific computing, artificial intelligence, or AI, data science, autonomous vehicles, or AV, robotics, and augmented and virtual reality, or AR and VR. The GPU was initially used to simulate human imagination, enabling the virtual worlds of video games and films. Today, it also simulates human intelligence, enabling a deeper understanding of the physical world. Its parallel processing capabilities, supported by up to thousands of computing cores, are essential to running deep learning algorithms. This form of AI, in which software writes itself by learning from data, can serve as the brain of computers, robots and self-driving cars that can perceive and understand the world. GPU-powered deep learning is being adopted by thousands of enterprises to deliver services and products that would have been impossible with traditional coding. NVIDIA has a platform strategy, bringing together hardware, software, algorithms, libraries, systems, and services to create unique value for the markets we serve. While the requirements of these end markets are diverse, we address them with a unified underlying architecture leveraging our GPUs and software stacks. The programmable nature of our architecture allows us to support several multi-billion-dollar end markets with the same underlying technology by using a variety of software stacks developed either internally or by third party developers and partners. The large and growing number of developers across our platforms strengthens our ecosystem and increases the value of our platform to our customers.
3-18-2022 |
Mr. Jen-Hsun Huang
President NVIDIA Corporation 2788 San Tomas Expressway Santa Clara, CA 95051 United States 408-486-2000 http://www.nvidia.com Nasdaq Stock Symbol NVDA |
|
Oaktree is a leading global alternative investment management firm with expertise in investing in credit, real assets, private equity, and listed equities. Oaktree’s mission is to deliver superior investment results with risk under control and to conduct its business with the highest integrity. Oaktree emphasizes an opportunistic, value-oriented and risk-controlled approach to its investments. Over the last three decades, Oaktree has developed a large and growing client base through its ability to identify and capitalize on opportunities for attractive investment returns in less efficient markets.
3-14-2022 |
Mr. Armen Panossian
Chief Executive Officer Oaktree Capital Group, LLC 333 South Grand Avenue 28th Floor Los Angeles, CA 90071 United States 213-830-6300 http://www.oaktreecapital.com NYSE Stock Symbol OAK |
|
Okta is the leading independent identity provider. Our vision is to free anyone to safely use any technology, and we believe identity is the key to making that happen. Our mission is to bring simple and secure digital access to people and organizations everywhere. The Okta Identity Cloud is powered by our category-defining platform that enables our customers to securely connect the right people to the right technologies and services at the right time.
3-07-2022 |
Mr. Todd McKinnon
Chairman Okta, Inc 301 Brannan Street 1st Floor San Francisco, CA 94107 United States 888-722-7871 http://www.okta.com Nasdaq Stock Symbol OKTA |
|
Omnicell, a leader in transforming the pharmacy care delivery model, is committed to elevating the role of pharmacy within healthcare and transforming medication management as an essential component of care delivery. We are doing so with an industry-leading comprehensive intelligent infrastructure, bringing together technology, analytics, and expert services to equip and empower pharmacists and pharmacies to focus on clinical care rather than administrative tasks. This intelligent infrastructure provides the critical foundation for realizing the industry vision of the Autonomous Pharmacy, a vision defined by pharmacy leaders for improving operational efficiencies and ultimately targeting zero-error medication management.
2-25-2022 |
Mr. Randall A. Lipps
Chairman Omnicell, Inc 590 East Middlefield Road Mountain View, CA 94043 United States 650-251-6100 http://www.omnicell.com Nasdaq Stock Symbol OMCL |
|
One Stop Systems, Inc. (“OSS” or the “Company”) designs, manufactures, and markets specialized high-performance computing modules and systems, which are designed to target edge computing deployments. Edge computing is a form of computing that is done on site, near a particular data source or the user (rather than in the cloud), minimizing the need for data to be processed in a remote data center. This growing trend increases computing performance and security as the data does not have to travel to some distant data center location. These specialized modules and systems consist of computers and storage products that incorporate the latest state-of-the art components with our embedded proprietary software. Such modules and systems allow our customers to offer high-end computing capabilities (often integrated within their equipment) to their target markets and applications.
3-24-2022- |
Mr. David K. Raun
Chief Executive One Stop Systems, Inc 2235 Enterprise Street Suite 110 Escondido, CA 92029 United States 760-745-9883 www.onestopsystems.com Nasdaq Stock Symbol OSS |
|
We developed NARCAN® (naloxone hydrochloride) Nasal Spray (“NARCAN®”), a treatment to reverse opioid overdose. This product was conceived and developed by us, licensed to Adapt Pharma Operations Limited (“Adapt”), an Ireland based pharmaceutical company in December 2014 and approved by the FDA in November 2015. Emergent BioSolutions, Inc. acquired Adapt in October of 2018 and Adapt became its wholly owned subsidiary (collectively with Adapt, "EBS"). In exchange for licensing our treatment to EBS, we receive up to double-digit percentage royalties on net sales.
3-15-2022 |
Dr. Roger Crystal
CEO Opiant Pharmaceuticals, Inc 201 Santa Monica Boulevard Suite 500 Santa Monica, CA 90401 United States 310-598-5410 http://www.opiant.com Nasdaq Stock Symbol OPNT |
|
Oracle provides products and services that address enterprise information technology (IT) environments. Our products and services include enterprise applications and infrastructure offerings that are delivered worldwide through a variety of flexible and interoperable IT deployment models. These models include on-premise deployments, cloud-based deployments, and hybrid deployments (an approach that combines both on-premise and cloud-based deployment) such as our Oracle Cloud@Customer offering (an instance of Oracle Cloud in a customer’s own data center). Accordingly, we offer choice and flexibility to our customers and facilitate the product, service and deployment combinations that best suit our customers’ needs. Our customers include businesses of many sizes, government agencies, educational institutions and resellers that we market and sell to directly through our worldwide sales force and indirectly through the Oracle Partner Network. Using Oracle technologies, our customers build, deploy, run, manage and support their internal and external products, services and business operations including, for example, a global cloud applications developer that utilizes Oracle Cloud Infrastructure (OCI) to power its software-as-a-service (SaaS) offerings; a multi-national financial institution that runs its banking applications using the Oracle Exadata Database Machine; and a global consumer products company that leverages Oracle Fusion Cloud Enterprise Resource Planning for its accounting processes, consolidation and financial planning functions.
6-21-2022 |
Ms. Safra Ada Catz
Chief Executive Officer Oracle Corporation 500 Oracle Parkway Redwood City, CA 94065 United States 650-506-7000 http://www.oracle.com NYSE Stock Symbol ORCL |
|
Organovo Holdings, Inc. (“Organovo Holdings,” “we,” “us,” “our,” the “Company” and “our Company”) is an early-stage biotechnology company that focuses on building high fidelity, 3D tissues that recapitulate key aspects of human disease. We use these models to identify gene targets responsible for driving the disease and intend to initiate drug discovery programs around these validated targets. We are initially focusing on the intestine and have ongoing 3D tissue development efforts in ulcerative colitis (“UC”) and Crohn’s disease (“CD”). We intend to add additional tissues/diseases/targets to our portfolio over time. In line with these plans, we are building upon both our external and in-house scientific expertise, which will be essential to our drug development effort.
6-10-2022 |
Mr. Keith E. Murphy
Chairman Organovo Holdings, Inc 6275 Nancy Ridge Drive Suite 110 San Diego, CA 92121 United States 858-224-1000 http://www.organovo.com Nasdaq Stock Symbol ONVO |
|
We are a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our existing HiFi long read sequencing technology and our emerging short read Sequencing by Binding (SBB®) technology. Our products address solutions across a broad set of applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. Our focus is on providing our customers with advanced sequencing technologies with higher throughput and improved workflows that we believe will enable dramatic advancements in routine healthcare. Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies and agricultural companies.
2-28-2022 |
Mr. Christian O. Henry
Chief Executive Officer Chairman Pacific Biosciences of California, Inc 1305 O'Brien Drive Menlo Park, CA 94025 United States 650-521-8000 http://www.pacb.com Nasdaq Stock Symbol PACB |
|
Palo Alto Networks, Inc. is a global cybersecurity provider with a vision of a world where each day is safer and more secure than the one before. We were incorporated in 2005 and are headquartered in Santa Clara, California. We empower enterprises, service providers, and government entities to secure all users, applications, data, networks, clouds and devices with comprehensive visibility and context continuously across all locations. We deliver cybersecurity products covering a broad range of use cases, enabling our end-customers to secure their networks, remote and hybrid workforces, branch locations, and public and private clouds, and to advance their Security Operations Centers (“SOC”). We believe our portfolio offers advanced prevention and security, while reducing the total cost of ownership for organizations by improving operational efficiency and eliminating the need for siloed point products
9-03-2021 |
Mr. Nikesh Arora
Chairman Palo Alto Networks, Inc 3000 Tannery Way Santa Clara, CA 95054 United States 408-753-4000 www.paloaltonetworks.com NYSE Stock Symbol PANW |